American Journal of Medical and Health Sciences
Volume-1 Issue-1 April-2022

The Interference of Commercialized Science in the Right to Mental Health

Dr Nalini kanta Sahoo

SRM Modinagar college of Pharmacy, Delhi, India.

Email: principal.pharmacy.ncr@srmist.edu.in

Abstract:

The necessity for a rights-based approach to mental health is universally acknowledged; yet, there is dispute about how best to conceptualize and implement it. Psychiatry has become overly focused on intra-individual solutions, such as increasing individuals' access to biomedical treatments, as a result of the dominance of the medical model and the influence of industry on the field. As a result, there has been a diminished appreciation for the social and psychological determinants of health, as well as the importance of population-based health promotion. A comprehensive rights-based approach to mental health is advocated in this study in order to counteract the negative impacts of economic interests on the mental health profession. We demonstrate how commercialized research the use of knowledge largely to fulfill the requirements of industry diverts attention away from the sociopolitical determinants of health, and we propose reforms to remedy the situation.

Keywords: Mental Health, Psychiatry, Psychological, Sociopolitical, Conceptualize

I INTRODUCTION

Human rights are not only entitlements with legal and ethical force, but they are also "fundamental foundations of justice and civilization," according to the United Nations. The Committee on Economic, Social, and Cultural Rights (CESCR) of the United Nations (UN) published its general opinion on the right to health more than two decades ago. This statement was officially adopted, which further cemented the need of nations to make the right to health a priority. The right to health has been recognized as a vital component of the right to health during the past two decades, and it is now widely accepted that it must be addressed in order for this right to be achieved. 'Without real physical health, there can be no true mental health,' said the first director-general of the World Health Organization (WHO), who also served as its first secretary-general.

There are, however, several obstacles to overcome in order to bring a rights-based approach to mental health to reality. To take this approach, it is necessary to conduct a critical examination of the assumptions made about mental illness as well as standard paradigms of treatment. It has been difficult to build mental health policy "as a viable cross-sectoral problem" because of the dominance of the medical paradigm and over-reliance on organized psychiatry as the primary policy maker, according to the authors. 4 The consequence has been an overemphasis on biological treatments focused at individuals rather than population-based health promotion, despite the fact that the latter is equally as essential as individual health care in terms of impact on health. Particularly troubling is the emphasis on biological therapies, which is due to the ways in which industrial involvement has undermined the scientific evidence foundation in medicine.

It is necessary to devote more attention to mental health in order to counteract the negative impacts of economic interests on the mental health profession. To be more specific, we demonstrate how commercialized science the application of science primarily to meet the needs of industry diverts attention away from the psychosocial and sociopolitical determinants of health and undermines several key elements of a rights-based approach to mental health, including the right to participate, the right to acceptable health care, and the importance of population-based health interventions.

Collaborations between academia and industry are recognized for igniting innovation and resulting in advantages to the general public's health and well-being (for example, treatments for malaria and the vaccine to prevent meningitis). The strains of capitalism, on the other hand, have resulted in a corrosive effect on the scientific evidence base, the medical education system, and even the lens through which human health and sickness are seen. Indeed, research has repeatedly shown that commercial influence is a pervasive issue throughout the whole health-care system, not just in hospitals. The scientific evidence base has been corrupted, notwithstanding differences of opinion over the amount of bias. This is a consensus among researchers, doctors, scientific communities, and medical organizations. Financial conflicts of interest have been regularly shown to influence prescription practices, medical education, guideline recommendations, and editorial choices, according to the research.

A report issued in 2009 by the Institute of Medicine (now the National Academy of Medicine) called Conflicts of Interest in Medical Research, Practice, and Education made suggestions for restoring integrity to medical research, practice and education. In 2010, an international committee of researchers and doctors examined the progress that had been achieved and came to the conclusion that there is still "widespread financial dependency on business [which] introduces commercial bias into research findings, medical education, and clinical practice." The public health consequences of prejudice coming from excessive business influence, particularly when considered in aggregate, are enormous. In spite of the fact that all medical specialties must contend with commercial bias and the damage it does to patients, psychiatry is especially susceptible due to the absence of biological indicators for any mental health issues. When it comes to the subject

of psychiatry, commercialized science suffocates an appreciation for epistemic variety (that is, a respect for a wide range of languages of pain) by supporting a reductive scientific illness paradigm, according to the American Psychological Association. As a consequence, the "professionalization of suffering" occurs, which helps to maintain the power of psychiatrists and other mental health experts over those who have suffered through a traumatic event. It is all too easy to overlook the right to participation and autonomy decision-making, as well as the freedom to reject a suggested therapy, in the sake of improving "adherence to treatment." As a result of the extensively promoted disease model of mental illness, a variety of systemic procedures have been implemented that have unwittingly entrenched prejudice in health care services, such as compulsory hospitalization when there is no urgent threat to oneself or others. It is common in low- and middle-income nations to employ sickness language and disease metrics (for example, the disability-adjusted life year) to draw attention to the economic impact of mental illness. Within four main categories, the following section provides a succinct overview of the commercialization of psychiatric science: psychiatric taxonomy, psychotropic medication trials, clinical care recommendations, and medical education are some of the topics covered in this course.

II LIMITING MENTAL DISTRESS TO A BIOMEDICAL MODEL

The prevalent psychoanalytic zeitgeist of the early twentieth century had a significant impact on the development of the Diagnostic and Statistical Manual of Mental Disorders (DSM). DSM I and DSM II were as a consequence characterized by a descriptive emphasis rather than precise demarcations between different types of diseases.

However, with the publishing of the DSM III in 1980, the American Psychiatric Association, the book's creator, embraced a medical framework and applied a "symptom checklist" method, marking the beginning of a new era in mental health diagnosis. With the third edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-III) and continuing with each new edition of the DSM, the conceptualization of emotional distress (as well as mental health conditions such as schizophrenia) encourages a view of people as patients with identifiable, quantifiable mental illnesses. As a result of this paradigm shift, standardization was made possible (for example, are symptom criteria for mental illness met?), but it also diverted focus away from issues regarding how structural changes at the community level may improve emotional well-being.

Furthermore, the adoption of a disease model helped to establish organized psychiatry's position within the area of mental health. As a result of the DSM's categorical approach, which emphasizes the identification of distinct symptomatology and the widening of diagnostic boundaries, the notion of "a medication for every sickness" is reinforced. The development of a diagnostic taxonomy that was business-friendly was not the objective of organized psychiatry; yet, Dr. Robert Spitzer, chair of DSM III, subsequently stated that "the pharmaceutical industry was happy" with

the medical paradigm that was embraced by DSM. The fact that the majority of the DSM IV and DSM V panel members had financial ties to the manufacturers of psychotropic medications used to treat the disorders described in the manual has sparked concerns about the pharmaceutical industry exerting undue influence over the manual's development and revision. Psychotropic medication trials are influencing the agenda and the evidence in a positive manner. In addition to matching the very definitions of mental disease with its financial interests, the pharmaceutical industry also has a significant influence over a large portion of the present body of knowledge. However, although the National Institutes of Health in the United States and government organizations in other countries support fundamental scientific studies, business funds the vast majority of clinical research that is relied on by physicians and policymakers. This "ghost management" not only establishes the research agenda, but it also normalizes the interaction between academia and industry.

This entanglement has an impact on the interpretation of the data and the research that is conducted as a result of it. To provide an example, it has been shown on several occasions in all sectors of medicine that the published results of industry-sponsored research "tend to favor sponsors' goods, thereby producing a ‘sponsorship bias'." Studies in psychiatry that disclosed financial conflicts of interest were almost five times more likely to produce good outcomes than those that did not. Among the factors contributing to this "funding impact" include the adoption of disease-oriented outcome metrics and an emphasis on statistical rather than clinical significance.Indeed, commercial sponsorship of phase III randomized clinical trials for psychiatric medications typically leads in the publishing of data that are favorable to the company, an overestimation of effectiveness, and an underreporting of adverse effects.

The financing impact may present itself in a variety of subtle but significant ways. Authors of clinical trials who have financial conflicts of interest, such as Veronica Yank et al., have discovered that they are more likely to write favorable conclusions even when the trial outcomes are negative. In light of this result, it may be concluded that commercial intervention is most likely founded in implicit prejudice and the establishment of "pro-industry habits of thinking." Clinical care standards are being used to spread the agenda. When authors have financial conflicts of interest or when the pharmaceutical or medical device business pays the research process, commercial influence on guideline development may occur (directly or indirectly). Professional society interests can also have an impact on research if the development group is not sufficiently multidisciplinary and does not include methodologists who can assist in making sure that evidence is not influenced by the interests of a professional society in the interpretation of the evidence There are concerns about undue industry influence raised by the fact that 90 percent of the authors of three major guidelines produced by the American Psychiatric Association for major depressive disorder, bipolar disorder, and schizophrenia had ties to the companies that manufactured the medications recommended as treatments for these disorders.

Recent developments include the publication of a new guideline for the treatment of depression in a peer-reviewed psychiatric journal, as well as extensive marketing of the guidelines to doctors and psychiatrists (for example, it was featured on Medscape and as a continuing medical education course). However, despite the availability of generic alternatives, the authors of this guideline advised pricey on-patent drugs without providing factual justification for their proposal. In a thorough independent review, it was discovered that the guideline failed to meet even one of the Institute of Medicine's standards for trustworthy guidelines, and that the majority of the authors of the guideline had ties to the manufacturer of the product that was recommended as a first-line treatment.

Medical education is being used to strengthen the hegemony. The pharmaceutical business, in addition to financing large areas of medical school research, works to establish a noncritical, friendly environment among medical students as early as possible in their training. Most medical students will have some kind of engagement with the pharmaceutical business at some time throughout their training, whether it be via meals, presents, books, or study aids. As a consequence, positive views about the sector are fostered in the community. 26 When physicians enter their practices, they continue to cultivate feelings of indebtedness or entitlement. As a result of this, new medications that have little or no advantage over older, less expensive medications are prescribed, resulting in the prescription of new medicines that have little or no advantage over older, less expensive medications.

It is also a serious issue that commercial assistance for continuous medical education (CME) is provided. Nearly three-quarters of the top 500 providers of continuing medical education get commercial financing, despite attempts by the accrediting body to limit the influence of business on content development. 28 It should come as no surprise that industry-sponsored continuing medical education has been condemned for incorporating marketing messages that are neither fair nor truthful. In an effort to "ensure that CME programs are impartial and devoid of commercial influence," the Accreditation Council for Continuing Medical Education establishes guidelines. However, more supervision and openness are still required. For example, doctors should be informed that, despite the council's monitoring, it is probable that commercial interests will continue to meddle with the content of educational activities, such as conferences. Following the National Academy of Medicine's concern that medical education has become nothing more than a marketing tool, the organization has called for an end to all links between industry and continuing medical education providers. Unfortunately, no one has taken notice of this call.

III RESULTS OF PRIORITY SETTING IN GLOBAL HEALTH

A human rights perspective on understanding emotional pain rekindles ethical dialogues regarding mental health since the drive for addressing well-being is built in an ethical, rather than an economic, reason for doing so. Framing a right as an economic benefit, as Gillian MacNaughton

and Diane Frey observe, diminishes its meaning and puts it as a component in an economic equation rather than as a component of a full existence. Making well-being a moral concern, on the other hand, allows us to get an even better understanding of the link between human rights and the social determinants of health, since we must take into account the immediate psychosocial environment in which symptoms originate. Thus, a comprehensive human rights strategy may address essential components of this connection in order to improve the well-being of people. It is apparent that rights and capabilities must be seen as interrelated entities, as articulated by Amartya Sen's capabilities approach (a moral framework that recognizes that the potential to acquire capacities is essential to human freedom and dignity). As a first step toward addressing this connection and ensuring that access to care and health equality are not confounded, we propose the following recommendations:

As a first step, more inclusion of persons who have been given psychiatric diagnoses or who identify as individuals with psychosocial impairments is required in order to design policies, programs, and standards of care that recognize and respond to a wide range of distressing idioms. Engagement should not be seen as an add-on, but rather as a "efficient and successful way to enhance health care systems and services." Such participation will aid in the expansion of suggested solutions outside the biological arena, which is critical. Because of this, persons who have first-hand knowledge of mental illness should be included in the planning, formulation, and distribution of mental health research and practice standards. This kind of inclusion will also aid in ensuring that commercial interests do not damage the integrity of the standards in any way. In addition, increased engagement of stakeholders will assist us in better understanding and challenging the institutional structures that contribute to the stigmatization of persons with psychosocial impairments, which will aid in the reduction of stigma. 36 Anti-stigma efforts must be grounded in a more sophisticated sociological understanding of stigma that recognizes it as social, relational, and structural in order to prevent what Flick Grey has characterized a process of "benevolent othering." A recent study conducted in Australia by the Queensland Mental Health Commission identified laws that were potentially stigmatizing, explained why they were possibly stigmatizing, and provided specific suggestions for their reform or repeal.

Because it is founded on the universality of human dignity, a rights-based perspective has the potential to halt the stigmatization process in its tracks. The availability of psychotropic drugs should not, in addition, be included in evaluations of governments' and responsibility bearers' compliance with a rights-based approach to public health. Interventions that do not take into account the social determinants of health would be in violation of the right to health and would not be in accordance with scientific evidence, respectively. 40 In order to improve the mental health status of populations, it is necessary to place population-based health on an equal footing with intra-individual treatments. This is because improving the mental health status of populations

cannot be accomplished simply by increasing access to medical and psychological treatments and services.

Examples include the Special Rapporteur on the right to health, who has consistently urged action on structural factors that cause distress, as well as calls on governments to invest in health promotion activities rather than simply focusing on increasing access to psychiatric diagnosis and treatment. Structured violence (the ways in which institutions and social systems harm populations and people) will likely be a difficult struggle to win since population-based remedies do not benefit industry in the same way that medicinal interventions do. However, as the Special Rapporteur has emphasized, we should not limit our evaluation of state human rights compliance to a single metric, such as the presence or absence of an essential medicines list; rather, we should broaden our scope to include psychosocial interventions in our assessments of state compliance.

V. CONCLUSION

When it comes to mental health, what are the prerequisites for a strong human rights-based approach? In spite of the fact that there are no simple solutions to this issue, it is essential to recognize that the shaky epistemological roots of psychiatry enable the mental health profession to be influenced by the pharmaceutical business. While it is undeniable that many individuals throughout the globe are not receiving adequate health care, it is equally undeniable that the uncritical importation of the biological illness paradigm will not result in maximally effective mental health therapies at the individual and population levels. It is true that increasing the number of people receiving mental health treatments in the absence of conceptual and structural competency may very possibly result in unanticipated human rights breaches (such as forced treatment). Despite the fact that it will be difficult, tackling the entrenched issue of commercial influence on the scientific evidence base is necessary if we are to see the implementation of a rights-based strategy through to completion.

REFERENCES

1. J. Pallasmaa, “Towards a neuroscience of architecture” in *Mind in Architecture: Neuroscience, Embodiment, and the Future of Design*, Eds. J. Pallasmaa,
2. H. F. Mallgrave, M. Arbib (MIT Press, 2013), pp. 5–21.
3. H. F. Mallgrave, *The Architect’s Brain: Neuroscience, Creativity, and Architecture* (John Wiley & Sons, 2010).
4. S. Robinson, J. Pallasmaa, *Mind in Architecture: Neuroscience, Embodiment, and the Future of Design* (MIT Press, 2015).
5. J. Pallasmaa, H. F. Mallgrave, M. A. Arbib, *Architecture and Neuroscience* (Tapio

Wirkkala-Rut Bryk Foundation, 2013).
6. R. Scruton, *The Aesthetics of Architecture* (Princeton University Press, Princeton, NJ, 1979).
7. Pé rez-Gó mez, *Attunement: Architectural Meaning after the Crisis of Modern Science* (MIT Press, 2016).
8. H. F. Mallgrave, *From Object to Experience: The New Culture of Architectural Design* (Bloomsbury Publishing, 2018).
9. Z. Djebbara, L. B. Fich, L. Petrini, K. Gramann, Sensorimotor brain dynamics reflect architectural affordances. *Proc. Natl. Acad. Sci. U.S.A.* 116, 14769–14778 (2019).
10. J. J. Gibson, *The Senses Considered as Perceptual Systems* (Houghton Mifflin Harcourt, Boston, MA, 1966).
11. J. J. Gibson, *The Ecological Approach to Visual Perception* (Houghton Mifflin Harcourt, Boston, MA, 1979).
12. P. Bozzi, "Experimental phenomenology: A historical profile" in *Shapes of Forms*, Ed. L. Albertazzi (Springer, Dordrecht, The Netherlands, 1999), pp. 19–50.
13. M. Kubovy, J. R. Pomerantz, *Perceptual Organization* (Lawrence Erlbaum Associates, Incorporated, Hillsdale, New Jersey, 1981).
14. T. D. Albright, G. R. Stoner, Contextual influences on visual processing. *Annu. Rev. Neurosci.* 25, 339–379 (2002).
15. J. Wagemans *et al*., A century of Gestalt psychology in visual perception: II. Conceptual and theoretical foundations. *Psychol. Bull.* 138, 1218–1252 (2012).
16. S. Gepshtein, Two psychologies of perception and the prospect of their synthesis. *Philos. Psychol*. 23, 217–281 (2010).
17. H. Gardner, *The Mind's New Science: A History of the Cognitive Revolution* (Basic Books, 1987).
18. U. Neisser, *Cognitive Psychology* (Prentice-Hall, Englewood Cliffs, NJ, 1967).
19. U. Neisser, *Cognition and Reality* (W. H. Freeman and Company, New York, NY, 1976).
20. J. Snider, M. Plank, G. Lynch, E. Halgren, H. Poizner, Human cortical θ during free exploration encodes space and predicts subsequent memory. *J. Neurosci.* 33, 15056–15068 (2013).
21. P. Dayan, L. F. Abbott, *Theoretical Neuroscience: Computational and Mathematical Modeling of Neural Systems* (MIT Press, 2005).
22. G. Pezzulo, P. Cisek, Navigating the affordance landscape: Feedback control as a process model of behavior and cognition. *Trends Cogn. Sci. (Regul. Ed.)* 20, 414–424 (2016).
23. T. J. Sejnowski, H. Poizner, G. Lynch, S. Gepshtein, R. J. Greenspan, Prospective optimization. *Proc. IEEE Inst. Electr. Electron. Eng.* 102, 799–811 (2014).
24. J. Snider, D. Lee, H. Poizner, S. Gepshtein, Prospective optimization with limited resources. *PLoS Comput. Biol.* 11, e1004501 (2015). 24
25. P. Bossaerts, C. Murawski, Computational complexity and human decision-making. *Trends Cogn. Sci. (Regul. Ed.)* 21, 917–929 (2017). 25 N. J. Lowe, *The Classical Plot and the Invention of Western Narrative* (Cambridge University Press, 2000), p. 63.